A clinical-stage biopharmaceutical company discovering and developing small molecule product candidates that target lysine-specific demethylase 1, or LSD1, an enzyme that plays a central role in the production of blood cells in the bone marrow. We are focused on improving the quality of life of patients with cancer and bone marrow diseases in addition to prolonging their lives.
Lead Underwriter
Cowen and Company, LLC, Guggenheim Securities, LLC, Jefferies LLC, Stifel Nicolaus & Company, Incorporated
